Shares in Pfizer and Moderna fell 3.9% and 7.4%, respectively, Friday after a report that the Trump administration plans to link the deaths of 25 children to COVID vaccines. Trump health officials ...
There are a lot of tutorials to get through early in Dying Light: The Beast. Many of them are helpful as you learn the ins and outs of the mechanics, but after a few hours, they can become an ...
Shares of companies that make COVID-19 vaccines sank Friday, after a report raised fears that Trump administration health officials will blame the vaccines for some child deaths. The Washington Post ...
Moderna, Inc. (NASDAQ:MRNA) shares are up nearly 5% on Tuesday after the company announced positive preliminary immunogenicity data for its 2025-2026 Spikevax formula, which targets the new LP.8.1 ...
Preliminary analysis showed the 2025-2026 formula of Spikevax generated greater than an 8-fold increase in LP.8.1-neutralizing antibodies across age groups Clinical findings reinforce preclinical data ...
Stocks of COVID-19 vaccine makers take a dive following Washington Post report, while Moderna stresses multiple agencies have backed their safety Stocks of COVID vaccine makers dropped after the ...
Moderna (MRNA) announced “positive” preliminary immunogenicity data for the 2025-2026 formula of Spikevax, which targets the LP.8.1 variant of SARS-CoV-2 to help prevent COVID-19. “The data from an ...
US pharmaceutical giant Moderna says it will deliver Australians the first batch of mRNA COVID-19 vaccines from its Melbourne plant by the end of this year as it unveiled plans to produce four other ...
Hosted on MSN
Carisma Therapeutics Amends Agreement with Moderna
Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. An update from Carisma Therapeutics ( ...
Attorney General Pam Bondi pledges to go after "hate speech," saying there's no place for it after Charlie Kirk’s assassination. But that isn't U.S. law under the First Amendment, and Kirk himself ...
Market headlines Moderna (MRNA) is seeing renewed investor interest due to improved revenue trends and upcoming product launches. However, the company faces challenges in diversifying beyond COVID-19 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback